270912-72-6

Usage

Uses

Used in Pharmaceutical Industry:
(R)-1-Boc-3-(aminomethyl)pyrrolidine is used as a synthetic intermediate for the development of novel pharmaceutical compounds. Its unique structure allows for the creation of new molecules with potential therapeutic applications, such as new drugs for the treatment of various diseases and disorders.
Used in Chemical Research:
In the field of chemical research, (R)-1-Boc-3-(aminomethyl)pyrrolidine is used as a key building block for the synthesis of complex organic molecules. Its reactivity and functional group compatibility make it an attractive candidate for the development of new synthetic routes and methodologies, which can be applied to the preparation of a wide range of target molecules.
Used in Material Science:
(R)-1-Boc-3-(aminomethyl)pyrrolidine can also be utilized in the development of new materials with specific properties. Its unique structure can be incorporated into the design of novel polymers, dendrimers, or other advanced materials with potential applications in various industries, such as electronics, energy storage, or environmental protection.

InChI:InChI=1/C10H20N2O2/c1-10(2,3)14-9(13)12-5-4-8(6-11)7-12/h8H,4-7,11H2,1-3H3/p+1/t8-/m0/s1

Upstream product

• 24424-99-5 di-tert-butyl dicarbonate 
• 67318-88-1 3-(aminomethyl)pyrrolidine 
• 93138-61-5 C-(1-benzyl-pyrrolidin-3-yl)-methylamine 
• 101385-93-7 3-oxo-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 476493-40-0 3-cyanopyrrolidine-1-carboxylic acid tert-butyl ester 
• 141699-57-2 3-methanesulfonyloxy-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 103057-44-9 N-(tert-butoxycarbonyl)-3-hydroxypyrrolidine 
• 72925-16-7 1-boc-pyrrolidine-3-carboxylic acid 
• 59379-02-1 tert-butyl 3-formylpyrrolidine-1-carboxylate 
• 849632-75-3 2,2,2-trifluoro-N-[(3RS)-3-pyrrolidinylmethyl]acetamide 
• 849632-74-2 2,2,2-trifluoro-N-{[(3RS)-1-(phenylmethyl)-3-pyrrolidinyl]methyl}acetamide 
• 1301188-94-2 1,1-dimethylethyl (3RS)-3-{[(trifluoroacetyl)amino]methyl}-1-pyrrolidinecarboxylate 
• 141699-56-1 3-methanesulfonyloxymethyl-pyrrolidine-1-carboxylic acid tert-butyl ester 
• 114214-69-6 tert-butyl 3-(hydroxymethyl)pyrrolidine-1-carboxylate 

Downstream Products

• 1301189-89-8 2-(4-biphenylyl)-1-[((3R₅)-1-{[(1,1-dimethylethyl)oxy]carbonyl}-3-pyrrolidinyl)methyl]-1H-benzimidazole-6-carboxylic acid 
• 1301189-91-2 1,1-dimethylethyl (3RS)-3-({2-(4-biphenylyl)-6-[(methylamino)carbonyl]-1H-benzimidazol-1-yl}methyl)-1-pyrrolidinecarboxylate 
• 1301189-92-3 2-(4-biphenylyl)-N-methyl-1-[(3RS)-3-pyrrolidinylmethyl]-1H-benzimidazole-6-carboxamide 
• 1301188-36-2 2-(4-biphenylyl)-1-({(3RS)-1-[(dimethylamino)carbonyl]-3-pyrrolidinyl}methyl)-N-methyl-1H-benzimidazole-6-carboxamide 
• 1301188-37-3 2-(4-biphenylyl)-N-methyl-1-({(3RS)-1-[(3-methyl-5-isoxazolyl)carbonyl]-3-pyrrolidinyl}methyl)-1H-benzimidazole-6-carboxamide 
• 1301189-87-6 3-{[((3RS)-1-{[(1,1-dimethylethyl)oxy]carbonyl}-3-pyrrolidinyl)methyl]amino}-4-nitrobenzoic acid 

Relevant academic research and scientific papers

A structure-guided optimization of pyrido[2,3-d]pyrimidin-7-ones as selective inhibitors of EGFRL858R/T790Mmutant with improved pharmacokinetic properties

Structural optimization of pyrido[2,3-d]pyrimidin-7-ones was conducted to yield a series of new selective EGFRT790Minhibitors with improved pharmacokinetic properties. One of the most promising compound 9s potently suppressed EGFRL858R/T790Mkinase and inhibited the proliferation of H1975?cells with IC50values of 2.0?nM and 40?nM, respectively. The compound dose-dependently induced reduction of the phosphorylation of EGFR and downstream activation of ERK in NCI[sbnd]H1975?cells. It also exhibited moderate plasma exposure after oral administration and an oral bioavailability value of 16%. Compound 9s may serve as a promising lead compound for further drug discovery overcoming the acquired resistance of non-small cell lung cancer (NSCLC) patients.

NEW ANTIBACTERIAL COMPOUNDS

The present invention relates to novel antibacterial compounds, pharmaceutical compositions containing them and their use as antimicrobials.

MULTIPLE KINASE PATHWAY INHIBITORS

Kinase with inhibitory activity against kinases disposed in multiple signaling pathways and their therapeutic uses.

FATTY ACID SYNTHASE INHIBITORS

This invention relates to carboxamides and reverse carboxamides according to Formula (I) and the use of carboxamides and reverse carboxamides for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of carboxamides and reverse carboxamides in the treatment of cancer.

BENZIMIDAZOLES AS FATTY ACID SYNTHASE INHIBITORS

This invention relates to the use of benzimidazole derivatives for the modulation, notably the inhibition of the activity or function of fatty acid synthase (FAS). Suitably, the present invention relates to the use of benzimidazoles in the treatment of cancer.

BENZIMIDAZOLE AND AZA-BENZIMIDAZOLE CARBOXAMIDES

This invention provides compounds of Formula I which are PAFR antagonists: I and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preve

BIARYL CARBOXAMIDES

This invention provides compounds of Formula (I) which are PAFR antagonists: Formula (I) and the pharmaceutically acceptable salts thereof. The compounds are useful for treating PAF-mediated disorders, and can be used in methods for treating atherosclerosis and preventing or reducing risk for atherosclerotic disease events. The compounds are also useful for treating or ameliorating pain, e.g. inflammatory pain and/or nociceptive pain, and for treating or ameliorating autoimmune and/or inflammatory diseases, among other conditions.

Cathepsin cysteine protease inhibitors

This invention relates to a novel class of compounds which are cysteine protease inhibitors, including but not limited to, inhibitors of Cathepsins K and L. These compounds are useful for treating diseases in which inhibition of bone resorption is indicated, such as osteoporosis.

Novel, nonpeptidic cyanamides as potent and reversible inhibitors of human cathepsins K and L

Compounds containing a 1-cyanopyrrolidinyl ring were identified as potent and reversible inhibitors of cathepsins K and L. The original lead compound 1 inhibits cathepsins K and L with IC50 values of 0.37 and 0.45 μM, respectively. Modification of compound 1 by replacement of the quinoline moiety led to the synthesis of N-(1-cyano-3-pyrrolidinyl)benzenesulfonamide (2). Compound 2 was found to be a potent inhibitor of cathepsins K and L with a Ki value of 50 nM for cathepsin K. Replacement of the 1-cyanopyrrolidine of compound 2 by a 1-cyanoazetidine increased the potency of the inhibitor by 10-fold. This increase in potency is probably due to an enhanced chemical reactivity of the compound toward the thiolate of the active site of the enzyme. This is demonstrated when the assay is performed in the presence of glutathione at pH 7.0 which favors the formation of a GSH thiolate anion. Under these assay conditions, there is a loss of potency in the 1-cyanoazetidine series due to the formation of an inactive complex between the GSH thiolate and the 1-cyanoazetidine inhibitors. 1-Cyanopyrrolidinyl inhibitors exhibited time-dependent inhibition which allowed us to determine the association and dissociation rate constants with human cathepsin K. The kinetic data obtained showed that the increase of potency observed between different 1-cyanopyrrolidinyl inhibitors is due to an increase of kon values and that the association of the compound with the enzyme fits an apparent one-step mechanism. 13C NMR experiments performed with the enzyme papain showed that compound 2 forms a covalent isothiourea ester adduct with the enzyme. As predicted by the kinetic analysis, the addition of the irreversible inhibitor E64 to the enzyme-cyanopyrrolidinyl complex totally abolished the signal of the isothiourea bond as observed by 13C NMR, thereby demonstrating that the formation of the covalent bond with the active site cysteine residue is reversible. Finally, compound 2 inhibits bone resorption in an in vitro assay involving rabbit osteoclasts and bovine bone with an IC50 value of 0.7 μM. 1-Cyanopyrrolidine represents a new class of nonpeptidic compounds that inhibit cathepsin K and L activity and proteolysis of bone collagen.

Pyrrolidine derivatives-CCR-3 receptor antagonists

This invention relates to certain 3-aminomethylpyrrolidine derivatives of Formula (I): that are CCR-3 receptor antagonists, pharmaceutical compositions containing them, methods for their use and methods for preparing these compounds.